MAM
BMRN icon

Marquette Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marquette Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$960 Hold
16
– – ﹤0.01% 655
2026
Q2 		$916 Buy
+16
New +$876 ﹤0.01% 741
2025
Q4 		– Sell
-54
Closed -$2.92K – 725
2025
Q3 		$2.92K Buy
+54
New +$3.09K ﹤0.01% 436

Other funds holding BMRN

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
FFBTD
First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Marquette Asset Management's BMRN Position: Q3 2026 in Review

Marquette Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 16 shares worth $960. The position accounts for ﹤0.01% of the portfolio, ranked #655.

Marquette Asset Management first reported a position in BMRN in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.92K in Q3 2025. 22 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Marquette Asset Management held 16 shares of BioMarin Pharmaceuticals worth $960 as of Q3 2026.
  • Marquette Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Marquette Asset Management's portfolio in Q3 2026, its #655 holding.
  • Marquette Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Marquette Asset Management's BioMarin Pharmaceuticals position peaked at $2.92K in Q3 2025.
  • 22 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Marquette Asset Management's 13F filing for Q3 2026, filed 9 Oct 2026.